GSK’s BENLYSTA (Belimumab) Treatment for Lupus and Adult Active Lupus Nephritis
Dr. Tania Gonzalez-Rivera, MD, BENLYSTA Global Medical Affairs Lead at GlaxoSmithKline (GSK) discusses the recent FDA approval of BENLYSTA (Belimumab) the first and only approved biologic treatment for both lupus and adult patients with active lupus nephritis who are receiving standard therapy. This approval builds on 10 years of clinical evidence.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Therapy. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Therapy and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Therapy?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Key Takeaways
- Key Point: Tania Gonzalez-Rivera, MD, BENLYSTA Global Medical Affairs Lead at GlaxoSmithKline (GSK) discusses the recent FDA approval of BENLYSTA (Belimumab) the first and only approved bi…
- Key Point: This approval builds on 10 years of clinical evidence. Tania C.
- Key Point: González-Rivera, MD, BENLYSTA Global Medical Affairs Lead at GlaxoSmithKline (GSK), has a deep breadth of experience in Medical Affairs spanning a variety of therapeutic areas.
- Key Point: As a board-certified rheumatologist with clinical expertise in systemic lupus erythematosus (SLE) and other complex autoimmune diseases, she also has extensive knowledge regardi…
- Key Point: González-Rivera earned her Doctor in Medicine and completed her Residency in Internal Medicine at the University of Puerto Rico School of Medicine, and completed her Rheumatolo…
Tania C. González-Rivera, MD, BENLYSTA Global Medical Affairs Lead at GlaxoSmithKline (GSK), has a deep breadth of experience in Medical Affairs spanning a variety of therapeutic areas. As a board-certified rheumatologist with clinical expertise in systemic lupus erythematosus (SLE) and other complex autoimmune diseases, she also has extensive knowledge regarding clinical trials and a background in translational research for SLE and lupus nephritis (LN). Dr. González-Rivera earned her Doctor in Medicine and completed her Residency in Internal Medicine at the University of Puerto Rico School of Medicine, and completed her Rheumatology Fellowship at the University of Michigan.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.



